We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDER Guidance Agenda for 2022 Features Clinical Trials, Generics
CDER Guidance Agenda for 2022 Features Clinical Trials, Generics
The FDA’s Center for Drug Evaluation and Research (CDER) plans to publish almost 100 new and revised draft guidances this year, according to the center’s 2022 guidance agenda — about two-thirds of which were previously on CDER’s 2021 agenda.